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Abstract A series of nine hitherto unknown bicylic pyrimidine nucleoside analogues (BCNAs) bearing bicyclic furo[2,3-d]pyrimidin-2(3H)-one, 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one and 5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one bases were prepared in a straightforward approach. The synthesised compounds posses β-D-rybofuranose or β-D-2-deoxyrybofuranose or β-D-arabinofuranose moieties attached to each of the heterocylic ring systems. This is one of a few examples of synthesis of pyrrolo[2,3-d]pyrimidin-2(7H)-one and dihydropyrimido[4,5-c]pyridazin-7(8H)-one nucleosides, and the first example of such nucleosides possessing arabinose moiety. A key synthetic step was a Sonogashira coupling reaction. For coupling with 4-phenyl-1-butyne, we used deprotected 5-iodouridine, 2’-deoxy-5-iodouridine, and 5-iodoarabinouridine and this reaction was followed by cycloisomerization and subsequent conversion of the furane ring into a pyrole ring or a pyridiazine. This approach resulted in the creation of small library of compounds, which were evaluated for their antiproliferative properties against HL-60 and Jurkat E6.1 cell lines. Of all tested compounds, only 3-(β-D-rybofuranosyl)-6-(2-phenylethyl)furo[2,3-d]pyrimidin-2(3H)-one exhibited weak anti-proliferative activity, with IC50 values of 54 and 81 µM for HL-60 and Jurkat E6.1 cells, respectively. 
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Bicyclic pyrimidine nucleoside analogues (BCNAs) serve as a convenient scaffold for the design and development of valuable drug candidates. Derivatives possessing furo[2,3-d]pyrimidine or pyrrolo[2,3-d]pyrimidin-2(7H)-one bases are well-recognized antiviral compounds, exhibiting activity against various RNA and DNA viruses e.g. VZV [1], HCMV [2], HCV [3] HBV [4] and vaccinia virus (VACV) [5]. Some other derivatives possessing oxazolo[5,4-d]pyrimidine [6] and thieno[5,4-d]pyrimidine [7] bases exhibit remarkable in vivo and in vitro anti-leukemic activity against L1210 cells, a therapeutic effect also observed for the 4’,5’-didehydro-L-ascorbic acid derivatives possessing bicyclic furo[2,3-d]pyrimidine bases [8]. 
However, there are few published reports concerning the biological activity of purine nucleosides modified with phenylethynyl or phenylethyl groups (Fig. 1). Volpini et al reports that introduction of phenylalkynyl group on C-8 of adenosine in compound 1 yields a very selective antagonist of the A3 adenosine receptor, exhibiting affinity to the receptor in the high nanomolar range [9]. Additionally, diphosphate 2, possessing a phenethyl group in C-2 position, was synthesised as a selective human P2Y1 receptor antagonist with antithrombotic properties [10]. 2-Phenylethyladenosine (3) was designed as a possible bacterial DNA ligase inhibitor with potential antibacterial activity [11], while truncated (N)-methanocarba adenosine derivatives of type 4, possessing alkyl or alkylaryl groups at the N6 position, were identified as highly potent and selective, low-efficacy partial agonists or antagonists of the A3AR receptor [12].

Figure 1 Bioactive purine nucleoside analogues bearing a phenylethynyl or phenylethyl group.

During our research we envisioned the possible synthesis of novel nucleoside analogues with potential anticancer activity. These compounds would possess bicyclic bases modified with a phenylethyl substituent, and various sugar-modified furanose rings (Scheme 1). In our research we decided to use furo[2,3-d]pyrimidin-2(3H)-one, 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one and 5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one as bicyclic bases, and ribose 2’-deoxyribose and arabinose as the sugar moieties. In contrast to the furo[2,3-d]pyrimidin-2(3H)-one nucleosides exhibiting a wide spectrum of antiviral activity, there are only a few literature reports concerning the synthesis of 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one and 5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one nucleosides, and no reports of such derivatives bearing arabinose moiety. It is known, however, that at least some nucleosides possessing bicyclic bases are recognized as efficient cytidine mimetics, forming stable Watson-Crick pairs with guanidine in DNA and RNA helix [13]. Therefore, we assumed that the designed compounds should be recognized and phosphorylated by cellular enzymes to the appropriate nucleoside triphosphates. We hypothesized that such triphosphates could inhibit DNA polymerases and therefore terminate DNA chain elongation, causing cancer cell death. Compounds possessing arabinose moiety attached to the 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one and 5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one bases could also be treated as bicyclic analogues of the anticancer drug Cytarabine (AraC) - an effective drug widely used for the treatment of acute myelogenous leukemia and lymphocytic leukemia [14]. In the designed analogues, an amine group is a part of pyrrole or pyridazine ring, thus these compounds would not be substrates for the cytidine deaminase (a main enzyme deactivating Cytarabine). This in consequence would improve bioavailability and extend the half-life of the compounds. We also assumed that the lipophilic substituent attached to the bicyclic moiety would increase the penetration of synthesized compounds through the blood-brain barrier. Working on a different research subject in our laboratory (unpublished data), we observed that the flexible phenenthyl substituent - when compared with rigid phenylethynyl group - increases and facilitates the possible interactions with enzyme receptor, and hence it could strengthen biological effect. 
Bicyclic pirymidine nucleoside analogues (BCNAs) can be synthesised by two general routes: a fusion reaction between sililated bicyclic nucleoside base with an appropriate sugar (Vorbrüggen reaction) [3b, 6-7, 15], or by modification of pyrimidine nucleosides by condensation/cyclisation reaction, and the resulting formation of novel pyrimidine-fused heterocyclic ring [1-2, 3a, 4-5].  For our purposes, we chose the second approach and applied 5-iodosubstituted pyrimidine nucleosides as convenient substrates easily transformed to the bicyclic analogues. Our syntheses were started either from commercially available (5-iodouridine and 5’-deoxy-2-iodouridine), or easily synthesised via direct iodination of unprotected nucleoside (5-iodoarabinouridine) [16] nucleosides 5a-c. In the first step they were applied to the Sonogashira reaction (Scheme 1). Obtained in this reaction 5-(4-phenyl-1-butynyl) nucleoside intermediate products 6a-c - accompanied by small amounts of target compounds 7a-c - were not separated, but directly transformed in a copper-catalyzed cycloisomerization reaction into the furo[2,3-d]pyrimidine derivatives 7a-c. Reaction showed moderate to good yields (44-69 %). Literature data shows, that furo[2,3-d]pyrimidine ring is quite susceptible for the nucleophilic attack by diverse nucleophiles, leading to the various modifications of pyrimidine ring. Reaction with hydroxide or alkoxide anions results in the opening of furan ring and formation of 5-(methylcarbonyl)uracils or 4-alkoxy-5-(carbonylmethyl)pyrimidines, respectively, while reaction with hydroxylamine results in the formation of N4-hydroxy-5-(methyl-N-hydroxyimino)cytosine derivatives [17]. In contrast, treatment of furo[2,3-d]pyrimidine nucleosides with nitrogen nucleophiles such as ammonia or hydrazine, leads to the formation of bicyclic nucleosides, 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one [3a] and 5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one derivatives [17], respectively, through the nucleophilic inducted ring opening/recyclization process. 










We observed that in contrast to the rather slow reaction with methanolic ammonia, treatment of 7a-c with 1N solution of hydrazine in THF - at room temperature - led to very fast conversion (less than 30 min.) to 5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one 9a-c nucleosides as sole products. We were pleased to observe that highly toxic, carcinogenic and dangerously unstable anhydrous hydrazine used in previous reports [15-16] could easily be replaced with its 1N solution in THF. Such replacement facilitates, and improves the transformation by providing much safer conditions, at the same time retaining a good yield of the transformation (42-54 %). The ORTEP drawings for 7b, 9a and 9b are presented on Figure 1.
All novel bicyclic nucleoside analogues 7a-c, 8a-c and 9a-c were tested for their anti-proliferative activity against HL-60 human promyelocytic leukemia cells and Jurkat E6.1 human acute T cell leukemia cells. Only compound 7a showed rather weak anti-proliferative activity with IC50 values of 54 and 81 µM for HL-60 and Jurkat E6.1 cells, respectively. Remaining compounds did not inhibit the proliferation rate of HL-60 and Jurkat E6.1 cells. The reference IC50 values calculated for Cytarabine were 0.185 and 0.018 µM for HL-60 and Jurkat E6.1 cells, respectively. 

Scheme 2 Synthesis of 3-(2-phenylethyl)-5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one 9a-c nucleoside analogues 
We have efficiently synthesised a series of nine hitherto unknown bicyclic pyrimidine nucleoside analogues bearing variations of three different bicyclic bases: furo[2,3-d]pyrimidin-2(3H)-one, 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one and 5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one and three different sugar moieties: β-D-rybofuranose, β-D-2-deoxyribofuranose and β-D-arabinofuranose. This is the first example of synthesis of 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one and              dihydropyrimido[4,5-c]pyridazin-7(8H)-one nucleosides possessing arabinose moiety. When tested for their antiproliferative effect, the synthesised compounds exhibited no, or weak cytotoxic activity. We assumed that due to their structural similarity to the natural nucleosides, synthesised compounds could be phosphorylated in cells to the appropriate triphosphates, but these products doesn’t exhibit significant effect on cell grow and death. Although, the synthesised compounds showed a rather weak cytotoxic activity on the investigated cell lines, the results and observed effects could help in the design of more active and selective inhibitors. 

Figure 2 ORTEP drawing showing 50% thermal ellipsoids of 9a (top), 9b (middle) and 7b (bottom). For numerical values of structural parameters see the Supporting Information.
The experimental section has no title; please leave this line here.
Chemistry: Commercially available chemicals were of reagent grade purity, and used as received. 5-iodouridine and 2’-deoxy-5-iodouridine were purchased (Carbosynth, United Kingdom), 5-iodoarabinouridine was synthesised according to the procedure described elsewhere [16]. The reactions were monitored by thin layer chromatography (TLC) analysis using silica gel plates (Kieselgel 60F254, E. Merck). Column chromatography was performed on Silica Gel 60M (0.040-0.063 mm, E. Merck). The 1H and 13C NMR spectra were recorded at the Chemistry Department of Warsaw University (Warsaw, Poland) using a Varian Unity Plus spectrometer (500 MHz) in DMSO-d6 and shift values were presented in parts per million (ppm) in relation to the internal reference - SiMe4. The resonance assignments are based on peak integration, peak multiplicity and 2D correlation experiments. Multiplets were assigned as s (singlet), d (doublet), t (triplet), ddd (doublet of doublet of doublet), m (multiplet). High Resolution Mass spectra were performed by the Laboratory of Mass Spectrometry, Institute of Biochemistry and Biophysics PAS (Warsaw, Poland) on a LTQ Orbitrap Velos (Thermo Scientific). IR spectra were recorded at FT/IR 6200 (Jasco) spectrometer in Laboratory of Optical Spectroscopy, Institute of Organic Chemistry PAS (Warsaw, Poland). The microwave-assisted reactions were performed in a Discover SP microwave reactor (CEM, United States) in 35ml glass tubes, setting 80 Watt input power at 60-65°C. Cell culture: HL-60 human promyelocytic leukemia cells and Jurkat E6.1 human acute T cell leukemia cells were obtained from the American Type Culture Collection (Rockville, Maryland U.S.A.) and maintained in the Cell Culture Collection of the Institute of Immunology and Experimental Therapy - Polish Academy of Sciences (IIET - PAS Wroclaw, Poland). Cells were maintained in RPMI-1640 GLUTAMAX (Gibco, Scotland, UK) medium containing 100 U/mL penicillin, 100 μg/mL streptomycin (both from Polfa Tarchomin S.A., Warsaw, Poland) and supplemented with 10% fetal bovine serum (Sigma-Aldrich, Germany). Medium for HL-60 cells was additionally supplemented with 1 mM sodium pyruvate and 4.5 g/L glucose (both from Sigma-Aldrich, Germany). Antiproliferative assays: Cells were plated on 96-well plates (Corning B.V. New York, USA) at a density of 1 × 104 cells per well in 100 μL of culture medium without FBS and antibiotics. After 24 hours of incubation under standard conditions (37 °C in a humid atmosphere with 5% CO2), cells were treated with Cytarabine analogues suspended in 100 mL of culture medium at final concentrations: 100 – 10 – 1 – 0.1 μg/mL. After additional 72 hours an MTT assay was applied as described earlier [18]. The optical densities of the samples were measured on a Synergy H4 Hybrid Reader (BioTek Instruments, USA). The Cytarabine was applied as a reference compound.
General procedure for the synthesis of furo[2,3-d]pyrimidin-2(3H)-one nucleosides (7)
1 mmol of appropriate iodonucleoside 5 (5-iodouridine, 2’-deoxy-5-iodouridine or 5-iodoarabinouridine, 1 eq.) was dissolved in 10ml of anhydrous DMF under Ar atmosphere. Added to this obtained solution were: 4-phenyl-1-butyne (3 eq.), triethylamine (1.9 eq.), copper iodide (0.2 eq.), and tetrakis(triphenylphosphine)palladium(0) (0.1 eq.), and the reaction mixture was stirred at room temperature for 24 hours. On the consecutive day the dark solution was heated to 50-60°C and more copper iodide (1.0 eq.) was added, and stirring was continued for an additional 12 hours. Volatiles were evaporated under reduced pressure and the residue was redissolved in methanol, then evaporated with silica gel and chromatographed using 10% methanol in chloroform. Analytically pure compounds were obtained by crystallization from methanol or acetone.
3-(β-D-ribofuranosyl)-6-(2-phenylethyl)furo[2,3-d]pyrimidin-2(3H)-one (7a). 
Yield 69%, white crystals; Mp 168.4-169.6 °C; Rf  = 0.67 (CHCl3-MeOH, 17:3).
IR (KBr): cm-1 3404, 3294, 3101, 3029, 2976, 2963, 2933, 2915, 2843, 1958, 1940, 1878, 1860, 1829, 1799, 1666, 1627, 1608, 1568, 1498, 1450, 1417, 1370, 1321, 1291, 1259, 1231, 1211, 1187, 1169, 1155, 1141, 1121, 1092, 1048, 1027.
1H NMR (500 MHz, dmso-d6): δ = 8.79 (s, 1H, H4), 7.26 (m, 4H, HAr), 7.18 (m, 1H, HAr), 6.37 (s, 1H, H5), 5.86 (d, J=2.5 Hz, 1H, H1’), 5.55 (d, J=4.5 Hz, 1H, OH2’), 5.24 (t, J=5.0 Hz, 1H, OH5’), 5.02 (d, J=4.5 Hz, 1H, OH3’), 3.97 (m, 3H, H2’+H3’+H4’), 3.80 (ddd, 1H, J1=2.5 Hz, J2=5.0 Hz, J3=12.5 Hz, H5’a), 3.64 (ddd, 1H, J1=2.5 Hz, J2=5.0 Hz, J3=12.5 Hz, H5’b), 2.97 (m, 4H, Hphen); 
13C NMR (125 MHz, dmso-d6): δ = 171.2, 157.6, 154.0, 140.3, 137.3, 128.4, 128.3, 126.2, 106.3, 100.2, 91.3, 84.1, 74.8, 68.2, 59.6, 32.2, 29.0. 
HRMS (ESI): m/z [M+H]+ calcd for C19H20N2O6: 373.13941, found: 373.13920.
3-(β-D-arabinofuranosyl)-6-(2-phenylethyl)furo[2,3-d]pyrimidin-2(3H)-one (7b).
Yield 44%, white crystals; Mp 199.9-205.5 °C;  Rf  = 0.67 (CHCl3-MeOH, 17:3).
IR (KBr): cm-1 3391, 3286, 3159, 3128, 3101, 3029, 2932, 2844, 1863, 1671, 1625, 1611, 1575, 1496, 1452, 1415, 1373, 1354, 1331, 1308, 1258, 1248, 1232, 1187, 1163, 1127, 1117,  1097, 1080.
1H NMR (500 MHz, dmso-d6): δ = 8.39 (s, 1H, H4), 7.26 (m, 4H, HAr), 7.19 (m, 1H, HAr), 6.40 (s, 1H, H5), 6.16 (d, J=3.5 Hz, 1H, H1’), 5.51 (d, J=4.0 Hz, 1H, OH2’), 5.46 (d, J=5.0 Hz, 1H, OH3’), 5.08 (t, J=5.5 Hz, 1H, OH5’), 4.13 (m, 1H, H2’), 3.96 (m, 1H, H3’), 3.89 (m, 1H, H4’),  3.65 (m, 2H, H5’), 2.98 (m, 4H, Hphen);  
13C NMR (125 MHz, dmso-d6): δ = 171.1, 157.0, 153.8, 140.3, 138.8, 128.4, 128.3, 126.2, 105.5, 100.3, 88.2, 86.2, 76.3, 74.4, 61.1, 32.3, 29.1. 
HRMS (ESI): m/z [M+H]+ calcd for C19H20N2O6: 373.13941, found: 373.13883.
3-(β-D-2-deoxyribofuranosyl)-6-(2-phenylethyl)furo[2,3-d]pyrimidin-2(3H)-one (7c). 
Yield 63%, white crystals; Mp 174.8-175.3 °C; Rf  = 0.70 (CHCl3-MeOH, 17:3).
IR (KBr): 3366, 3266, 3124, 3100, 3028, 2965, 2925, 2844, 1963, 1943, 1861, 1670, 1625, 1609, 1576, 1497, 1453, 1419, 1375, 1335, 1310, 1276, 1257, 1231, 1185, 1161, 1125, 1104, 1073, 1061, 1002 cm-1.
1H NMR (500 MHz, dmso-d6): δ = 8.66 (s, 1H, H4), 7.26 (m, 4H, HAr); 7.18 (m, 1H, HAr), 6.38 (s, 1H, H5),  6.17 (t, J=6.0 Hz, 1H, H1’), 5.28 (d, J=4.0 Hz, 1H, OH3’), 5.10 (t, J=5.5 Hz, 1H, OH5’), 4.23 (m, 1H, H3’), 3.91 (m, 1H, H4’),  3.67 (m, 1H, H5’a), 3.61 (m, 1H, H5’b), 2.96 (m, 4H, Hphen), 2.38 (m, 1H, H2’a), 2.04 (m, 1H, H2’a). 
13C NMR (125 MHz, dmso-d6): δ = 171.1, 157.4, 153.8, 140.3, 137.0, 128.4, 128.3, 126.1, 106.2, 100.3, 88.1, 87.4, 69.7, 60.8, 41.2, 32.2, 29.0. 
HRMS (ESI): m/z [M+H]+ calcd for C19H20N2O5: 357.14450, found: 357.14408.
General procedure for the synthesis of 3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one nucleosides (8)
Furo[2,3-d]pyrimidin-2(3H)-one nucleosides 7 were dissolved in the 7N methanolic ammonia (10ml by 1 mmol of nucleoside) in a microwave tube and reaction mixture was stirred in 60-65°C in the microwave oven (80 Watt) for 24 hours. Then, the reaction mixture was moved to the round-bottom flask, and the solvent was evaporated with silica gel. The final compounds were purified by column chromatography on silica gel using 15% methanol in chloroform. Analytically pure compounds were obtained by crystallization from methanol or acetone.
3-(β-D-ribofuranosyl)-6-(2-phenylethyl)-3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one (8a).  
Yield 45%, white crystals; Mp 191.2-192.3 °C; Rf  = 0.43 (CHCl3-MeOH, 17:3).
IR (KBr): 3397, 2977, 2925, 1658, 1618, 1588, 1556, 1496, 1454, 1408, 1375, 1285, 1258, 1195, 1100, 1044 cm-1.
 1H NMR (500 MHz, dmso-d6): δ = 11.23 (s, 1H, NH), 8.61 (s, 1H, H4), 7.22 (m, 5H, HAr), 5.93 (s, 1H, H5), 5.87 (s, 1H, H1’), 5.47 (d, J=3.0 Hz, 1H, OH2’), 5.24 (t, J=4.5 Hz, 1H, OH5’), 5.00 (d, J=5.0 Hz, 1H, OH3’), 3.99 (m, 2H, H2’+H3), 3.93 (m, 1H, H4’), 3.78 (m, 1H, H5’a), 3.62 (m, 1H, H5’b), 2.94 (m, 2H, Hphen), 2.84 (m, 2H, Hphen); 
13C NMR (125 MHz, dmso-d6): δ = 159.2, 154.2, 141.7, 140.9, 135.2, 128.32, 128.26, 126.0, 108.8, 96.7, 91.0, 84.1, 74.9, 68.6, 60.0, 33.5, 29.3. 
HRMS (ESI): m/z [M+H]+ calcd for C19H21N3O5: 372.15540, found: 372.15516.
3-(β-D-arabinofuranosyl)-6-(2-phenylethyl)-3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one (8b). 
Yield 54%, white crystals, Mp 224.6-225.2 °C; Rf  = 0.38 (CHCl3-MeOH, 17:3).
IR (KBr): 3242, 3024, 2936, 2911, 1659, 1621, 1590, 1567, 1558, 1496, 1453, 1415, 1381, 1446, 1264, 1199, 1151, 1112, 1075, 1054 cm-1.
 1H NMR (500 MHz, dmso-d6): δ = 11.19 (s, 1H, NH), 8.22 (s, 1H, H4), 7.26 (m, 4H, HAr), 7.16 (m, 1H, HAr), 6.20 (d, J=3.5 Hz, 1H, H1’), 5.92 (s, 1H, H5), 5.47 (d, J=4.0 Hz, 1H, OH3’), 5.37 (d, J=5.5 Hz, 1H, OH2’), 5.09 (t, J=5.5 Hz, 1H, OH5’), 4.08 (ddd, J1=2.0 Hz, J2=3.5 Hz, J3=5.5 Hz, H2’), 3.94 (ddd, J1=2.0 Hz, J2=2.5 Hz, J3=4.0 Hz, H3’), 3.85 (dt, J1=2.5 Hz, J2=5.5 Hz, H4’), 3.65 (t, J=5.5 Hz, 2H, H5’), 2.94 (t, J=7.5 Hz, 2H, Hphen), 2.84 (t, J=7.5 Hz, 2H, Hphen).
13C NMR (125 MHz, dmso-d6): δ = 159.1, 153.9, 141.0, 136.8, 128.32, 128.27, 126.0, 107.8, 96.8, 87.6, 85.7, 76.5, 74.5, 61.2, 33.6, 29.4. 
HRMS (ESI): m/z [M+H]+ calcd for C19H21N3O5: 372.15540, found: 372.15504.
3-(β-D-2’-deoxyribofuranosyl)-6-(2-phenylethyl)-3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one (8c). 
Yield 65%, white crystals; Mp 198.1-199.0 °C; Rf  = 0.49 (CHCl3-MeOH, 17:3).
IR (KBr): 3408, 2948, 2921, 2867, 2839, 1671, 1631, 1593, 1566, 1496, 1454, 1422, 1377, 1351, 1303, 1279, 1115, 1059, 1001 cm-1. 
1H NMR (500 MHz, dmso-d6): δ = 11.20 (s, 1H, NH), 8.48 (s, 1H, H4), 7.23 (m, 5H, HAr), 6.24 (t, J=6.0 Hz, 1H, H1’), 5.89 (s, 1H, H5),  5.23 (d, J=3.0 Hz, 1H, OH3’), 5.07 (t, J=5.5 Hz, 1H, OH5’), 4.22 (m, 1H, H3’), 3.86 (m, 1H, H4’),  3.62 (m, 2H, H5’a), 2.94 (m, 2H, Hphen), 2.84 (m, 2H, Hphen), 2.31 (m, 1H, H2’a), 1.98 (m, 1H, H2’a). 
13C NMR (125 MHz, dmso-d6): δ = 159.2, 153.9, 151.5, 140.9, 128.31, 128.25, 126.0, 108.7, 96.7, 87.8, 86.7, 70.0, 61.0, 41.4, 33.5, 29.3. 
HRMS (ESI): m/z [M+H]+ calcd for C19H21N3O4: 356.16048, found: 356.16038.
General procedure for the synthesis of 5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one nucleosides (9)
Furo[2,3-d]pyrimidin-2(3H)-one nucleosides 7 were dissolved in the 1N solution of hydrazine in THF (20ml by 1 mmol of nucleoside) and stirred at the RT for 1h. Then, the reaction mixture was moved to the round-bottom flask and the solvent was evaporated with silica gel. The final compounds were purified by column chromatography on silica gel using 15% methanol in chloroform. Analytically pure compounds were obtained by crystallization from methanol or acetone.
6-(β-D-ribofuranosyl)-3-(2-phenylethyl)-5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one (9a). 
Yield 42%, white crystals; Mp 216.6-217.3 °C; Rf  = 0.33 (CHCl3-MeOH, 17:3).
IR (KBr): 3348, 3233, 2935, 2921, 2869, 2848, 1655, 1578, 1473, 1416, 1390, 1380, 1344, 1325, 1307, 1290, 1267, 1249, 1209, 1165, 1129, 1102, 1077, 1014 cm-1.
1H NMR (500 MHz, dmso-d6): δ = 10.40 (s, 1H, NH), 7.41 (s, 1H, H4), 7.27 (m, 4H, HAr); 7.18 (m, 1H, HAr), 5.82 (d, J=6.0 Hz, 1H, H1’), 5.08 (d, J=5.5 Hz, 1H, OH2’), 4.95 (d, J=5.0 Hz, 1H, OH3’), 4.83 (t, J=5.5 Hz, 1H, OH5’), 4.43 (s, 2H, H5), 4.05 (m, 1H, H2’), 3.90 (m, 1H, H3’), 3.70(m, 1H, H4’),  3.55 (m, 1H, H5’a), 3.48 (m, 1H, H5’b), 3.09 (m, 2H, Hphen), 2.98 (m, 2H, Hphen); 
13C NMR (125 MHz, dmso-d6): δ = 157.8, 153.2, 151.8, 141.0, 128.4, 128.3, 126.0, 124.0, 120.5, 87.3, 83.4, 70.3, 69.7, 61.5, 39.9, 36.7, 34.8. 
HRMS (ESI): m/z [M+H]+ calcd for C19H22N4O5: 387.16630, found: 387.16593.
6-(β-D-arabinofuranosyl)-3-(2-phenylethyl)-5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one (9b). 
Yield 61%, white crystals; Mp 227.8-228.4 °C; Rf  = 0.36 (CHCl3-MeOH, 17:3).
IR (KBr): 3228, 2910, 2868, 1670, 1604, 1580, 1483, 1452, 1413, 1352, 1305, 1263, 1203, 1170, 1123, 1056, 1013 cm-1. 
1H NMR (500 MHz, dmso-d6): δ = 10.31 (s, 1H, NH), 7.39 (s, 1H, H4), 7.26 (m, 4H, HAr); 7.18 (m, 1H, HAr), 5.97 (d, J=6.0 Hz, 1H, H1’), 5.55 (d, J=4.5 Hz, 1H, OH2’), 5.32 (d, J=4.5 Hz, 1H, OH3’), 4.86 (t, J=5.5 Hz, 1H, OH5’), 4.60 (d, J=16.5 Hz, 1H, H5a), 4.48 (d, J=16.5 Hz, 1H, H5b), 4.06 (m, 1H, H2’), 3.86 (m, 1H, H3’), 3.67 (m, 1H, H4’),  3.56 (m, 2H, H5’), 3.08 (m, 2H, Hphen), 2.98 (m, 2H, Hphen); 
13C NMR (125 MHz, dmso-d6): δ = 157.8, 153.0, 152.0, 141.1, 128.4, 128.3, 126.0, 123.8, 120.8, 83.1, 81.0, 76.5, 75.4, 60.9, 41.6, 36.7, 34.8. 
HRMS (ESI): m/z [M+H]+ calcd for C19H22N4O5: 387.16630, found: 387.16586.
6-(β-D-2’-deoxyribofuranosyl)-3-(2-phenylethyl)-5,6-dihydropyrimido[4,5-c]pyridazin-7(8H)-one (9c). 
Yield 53%, white crystals; Mp 175.6-176.3 °C; Rf  = 0.47 (CHCl3-MeOH, 17:3).
IR (KBr): 3186, 3124, 3060, 2924, 2850, 1661, 1614, 1577, 1481, 1454, 1412, 1372, 1346, 1306, 1273, 1235, 1191, 1164, 1105, 1058, 1026 cm-1. 
1H NMR (500 MHz, dmso-d6): δ = 10.37 (s, 1H, NH), 7.41 (s, 1H, H4), 7.25 (m, 4H, HAr); 7.17 (m, 1H, HAr), 6.25 (m, 1H, H1’); 5.14 (d, J=4.5 Hz, 1H, OH3’), 4.80 (t, J=5.5 Hz, 1H, OH5’), 4.41 (s, 1H, H5); 4.16 (m, 1H, H3’), 3.63 (m, 1H, H4’),  3.49 (m, 2H, H5’), 3.08 (m, 2H, Hphen), 2.98 (m, 2H, Hphen), 2.14 (m, 1H, H2’a), 1.81 (ddd, 1H, J1=3.5 Hz, J2=6.5 Hz, J3=10.0 Hz, H2’a). 
13C NMR (125 MHz, dmso-d6): δ = 157.8, 152.8, 151.8, 141.0, 128.4, 128.3, 126.0, 124.1, 120.5, 85.9, 83.0, 70.5, 61.7, 39.0, 36.7, 35.1, 34.8. 
HRMS (ESI): m/z [M+H]+ calcd for C19H22N4O4: 371.17138, found: 371.17144.
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